Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Kitamura, Hiroshi; Yamamoto, Etsuhide; Nozaki, Shinichi; Wada, Shigehito; Furuta, Isao; Kurashina, Kenji

doi:10.1016/j.oraloncology.2004.05.002

Cited by 25 publications

(43 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment protocol for OSCC patients and their eligibility criteria were described previously. 23 Written informed consent was obtained from every patient. The Institutional Review Board reviewed and approved the protocol prior to commencement.…”

Section: Methodsmentioning

confidence: 99%

Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors

Ogi

Toyota

Mitsuya³

et al. 2005

Cancer Biology & Therapy

View full text Add to dashboard Cite

Alterations in the function of cell cycle checkpoints are frequently detected in oral squamous cell carcinomas (OSCCs), and are often associated with the sensitivity of the cancer cells to chemotherapeutic drugs. Recently, a mitotic checkpoint gene, Chfr, was shown to be inactivated by promoter methylation and point mutations in various human tumors. Here we show that the absence of its product, CHFR, is associated with mitotic checkpoint dysfunction, and that cancer cells lacking CHFR are sensitive to microtubule inhibitors. Checkpoint impairment appears to be caused by a prophase defect in this case, as OSCC cells lacking CHFR showed phosphorylation of histone H3 on Ser10 and translocation of cyclin B1 to the nucleus. When CHFR-deficient OSCC cells were treated with a microtubule inhibitor (docetaxel or paclitaxel), significant numbers of apoptotic cells were observed. Moreover, disruption of CHFR using small interfering RNA (siRNA) impaired the mitotic checkpoint, thereby reducing the ability of OSCC cells to arrest at G 2 /M phase and making them more sensitive to microtubule inhibitors. Our results suggest that CHFR could be a useful molecular target for chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors

Ogi

Toyota

Mitsuya³

et al. 2005

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Several studies have suggested that 18 F-FDG PET might be useful for assessment of therapeutic responses (3)(4)(5)(6). However, 18 F-FDG is also metabolized at sites of inflammation and in other reactive states, so that false-positive results may be obtained because of inflammatory changes remaining within the first few posttreatment months.…”

mentioning

confidence: 99%

“…However, 18 F-FDG is also metabolized at sites of inflammation and in other reactive states, so that false-positive results may be obtained because of inflammatory changes remaining within the first few posttreatment months.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Usefulness of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

et al. 2012

View full text Add to dashboard Cite

This study compared the utility of 39-deoxy-39-18 F-fluorothymidine PET ( 18 F-FLT PET) with that of 18 F-FDG PET for assessment of the early locoregional clinical outcomes of chemoradiotherapy for head and neck squamous cell carcinomas. Methods: From May 2006 to September 2010, 28 patients with head and neck squamous cell carcinomas underwent 18 F-FLT and 18 F-FDG PET before radiation therapy (RT), 4 wk after the initiation of RT, and 5 wk after completion of RT. PET images were evaluated qualitatively for regions of focally increased metabolism and were analyzed in relation to residual accumulation and local disease control. Results: During RT, 18 F-FLT uptake decreased more significantly than 18 F-FDG uptake. 18 F-FLT accumulations disappeared in 34 of 54 lesions (63%), and negative predictive value was 97%. 18 F-FDG PET during RT also had a high negative predictive value (100%), but only 9 lesions (16%) showed complete absence of accumulation. The specificity and overall accuracy of 18 F-FLT PET were significantly higher than those of 18 F-FDG PET both during and after RT. In particular, high significance was attributable to the results of the evaluations of primary lesions. There were significant differences in 3-y local control between the residual-accumulation and no-accumulation groups on both posttreatment 18 F-FLT PET (P , 0.0001) and posttreatment 18 F-FDG PET (P 5 0.0081). Conclusion: 18 F-FLT PET during RT and early follow-up facilitates the selection of optimal further therapy and the prediction of outcomes.

show abstract

“…However, CDDP commonly induces kidney dysfunction and nausea/vomiting. Due to the risk of renal damage and digestive tract disorders following treatment with this agent, Kurita et al (27) developed nedaplatin (NDP), a novel platinum complex with a different molecular structure but similar mechanism of action to that of CDDP, which is associated with a lower frequency of digestive symptoms and renal toxicity. Additionally, NDP has been shown to be as effective, or more effective, than CDDP in the treatment of head and neck cancers (28), and the combination of NDP with GEM, synergistically inhibited the growth of human lung cancer cells in a xenograft model (29).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

2015

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin chemotherapy regimen, followed by concurrent chemoradiotherapy or radiotherapy alone, in locoregionally advanced nasopharyngeal carcinoma (NPC). Eighty-six patients with stage III, IVA or IVB NPC, who received neoadjuvant chemotherapy [gemcitabine, 1,000 mg/m 2 on day 1 (d1) and d5; nedaplatin, 25 mg/m 2 on d 1-3] every 3 weeks for at least two cycles, followed by intensity-modulated radiotherapy every 3 weeks, with or without concurrent nedaplatin (25 mg/m 2 , d1-3) between September 2010 and December 2013, were retrospectively analyzed. By comparing pretreatment and post-treatment MRI images, it was shown that seven patients achieved a complete response (8.5%), while 66 achieved a partial response (80.5%), following completion of neoadjuvant chemotherapy (combined response rate, 89.0%). Grade 3-4 toxicities following neoadjuvant chemotherapy included neutropenia (29.1%), leukopenia (11.6%), liver dysfunction (9.3%), thrombocytopenia (9.3%) and nausea/vomiting (8.1%). The median follow-up was 18 months (range, 5-44 months). The 2-year relapse-free survival, distant metastasis-free survival, progression-free survival and overall survival rates were 96.6, 85.4, 83.3 and 96.1%, respectively. Compared with alternative neoadjuvant chemotherapy regimens in combination with radiotherapy or concurrent chemoradiotherapy, the present gemcitabine and nedaplatin did not provide additional survival benefit and led to a higher frequency of liver dysfunction. Therefore, neoadjuvant gemcitabine and nedaplatin should be used with caution in locoregionally advanced NPC.

show abstract

Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Cited by 25 publications

References 19 publications

Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors

Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors

Usefulness of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

Contact Info

Product

Resources

About

Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma

Cited by 25 publications

References 19 publications

Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors

Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors

Usefulness of 3′-Deoxy-3′-18F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer

Evaluation of the efficacy and safety of a neoadjuvant gemcitabine and nedaplatin regimen followed by radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma

Contact Info

Product

Resources

About

Usefulness of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Predicting Early Response to Chemoradiotherapy in Head and Neck Cancer